We went further to genome engineer a small (~10 bp) and large (~90 bp) promoter indel using CRISPR/Cas9 at this variant location in melanoma cell lines, which leads to decreased CDC20 expression, and then characterize the potential effects of the variant on in vitro and in vivo cell viability, migration, and global gene expression changes. This evidence concerns the gene CDC20 and melanoma.